do glp 1 agonists have cardiovascular benefit GLP-1 receptor and outcome trials: An update Can one drug do it

Of note, the mean basal insulin dose at the study endpoint (week 52) was 48.8 U with insulin degludec in the SURPASS-3 trial and 43.5 U with insulin glargine in the SURPASS-4 trial [20, 21]

Int J Epidemiol 44:82736

Non GLP-1 meds like Qysmia, Contrave, orlistat or metformin are also options to discuss with your provider

In addition, few studies currently support the use of GLP-1RAs in patients with HFrEF

The approach could begin by prioritizing treatment for patients most likely to benefit from GLP-1 drugs to reach specific weight loss targets

November 20, 2025: Ozempic Vision Loss and Gastroparesis Lawsuits Consolidated in New Jersey The New Jersey Supreme Court has approved the creation of two multicounty litigations (MCLs) involving Ozempic